Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049).

Trial Profile

Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049).

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs GSK 257049 (Primary) ; DTaP-hepatitis B vaccine; Hepatitis B vaccine recombinant; Measles virus vaccine live; Pneumococcal 11-valent vaccine conjugate; Poliovirus vaccine live oral; RIX 4414; Yellow fever vaccine
  • Indications Diphtheria; Hepatitis B; Measles; Pertussis; Pneumococcal infections; Poliomyelitis; Rotavirus infections; Tetanus; Yellow fever
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 05 Oct 2012 Planned end date changed from 1 Feb 2017 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 05 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top